SCHEMBL24500

SCHEMBL24500

COCCCNc1nccn2nc(Nc3cc(C)cc(C)c3)nc12

nearest known ligand 0.38

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
JAK2 O60674 6/20 0.38
PTK2 Q05397 6/20 0.38
KCNH3 Q9ULD8 1/20 0.38
LMNA P02545 1/20 0.38
HTT P42858 1/20 0.38
SMN1; SMN2 Q16637 1/20 0.38
HPGD P15428 1/20 0.38
SHMT2 P34897 1/20 0.38
KDM4E B2RXH2 2/20 0.37
KDR P35968 5/20 0.36
JAK3 P52333 1/20 0.36
FLT1 P17948 1/20 0.35
FLT4 P35916 1/20 0.35
ALDH1A1 P00352 1/20 0.35
PKM P14618 1/20 0.35
ZAP70 P43403 1/20 0.35
SYK P43405 1/20 0.35
PDE4B Q07343 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24180 0.90 PTK2 (0.44) JAK2PTK2KCNH3LMNAHTT
SCHEMBL23275 0.88 ZAP70 (0.44) JAK2PTK2KCNH3SHMT2KDR
SCHEMBL23499 0.86 KCNH3 (0.55) JAK2PTK2KCNH3LMNASHMT2
SCHEMBL23494 0.85 SYK (0.44) JAK2PTK2HTTSMN1; SMN2HPGD
SCHEMBL23452 0.84 SYK (0.45) JAK2PTK2KDRFLT1FLT4
SCHEMBL24256 0.82 EGFR (0.42) JAK2PTK2LMNAKDRJAK3
SCHEMBL15207316 0.81 KDM4E (0.44) JAK2PTK2LMNAKDM4EKDR
SCHEMBL23523 0.80 LMNA (0.48) JAK2PTK2LMNAHTTHPGD
SCHEMBL24392 0.76 ZAP70 (0.42) JAK2PTK2JAK3ZAP70SYK
SCHEMBL24685 0.76 EGFR (0.44) JAK2PTK2HPGDKDM4EKDR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9023851-B2 Triazolopyrazine derivatives MERCK PATENT GMBH (DE) 2015-05-05 US claimed
US-20130225568-A1 TRIAZOLOPYRAZINE DERIVATIVES MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) 2013-08-29 US claimed
EP-2609098-B1 TRIAZOLOPYRAZINE DERIVATIVES MERCK PATENT GMBH (DE) 2016-07-13 EP disclosed
US-9023851-B2 Triazolopyrazine derivatives MERCK PATENT GMBH (DE) 2015-05-05 US disclosed
US-9023851-B2 Triazolopyrazine derivatives MERCK PATENT GMBH (DE) 2015-05-05 US disclosed
US-20130225568-A1 TRIAZOLOPYRAZINE DERIVATIVES MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) 2013-08-29 US disclosed
US-20130225568-A1 TRIAZOLOPYRAZINE DERIVATIVES MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) 2013-08-29 US disclosed
WO-2012025186-A1 TRIAZOLOPYRAZINE DERIVATIVES MERCK PATENT GMBH (DE) 2012-03-01 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130225568-A1 TRIAZOLOPYRAZINE DERIVATIVES SYK, IRAK1, ZAP70 JAK2 5/4885PTK2 367/4885KCNH3 1428/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.